^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
08/30/2022
Excerpt:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma...SUGGESTED TREATMENT REGIMENS...CLL/SLL with del(17p)/TP53 mutation…Other recommended regimens…Ibrutinib + venetoclax…
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

Excerpt:
...- Cohort 2: Untreated patients with high-risk features (del(17p), or mutated TP53, or del(11q), or unmutated IGHV, or >= 65 years of age) are eligible (cohort 2) provided they have active disease requiring treatment as defined by the International Working Group for CLL (IWCLL)...
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.

Published date:
05/25/2023
Excerpt:
Pts aged ≤70 y with previously untreated CLL/SLL received 3 cycles of I then 12 cycles of I+V (I 420 mg/d orally; V ramp-up to 400 mg/d orally)….4 y PFS rates were numerically lower in pts with uIGHV (73%) or del(17p) and/or TP53 mutation (63%), while OS rates remained consistently high (Table)....With 4 y follow-up, fixed-duration I+V continues to provide deep, durable remissions with clinically meaningful PFS and time off treatment, including in pts with high-risk disease features.
DOI:
10.1200/JCO.2023.41.16_suppl.7535
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

032 | CAPTIVATE PRIMARY ANALYSIS OF FIRST-LINE TREATMENT WITH FIXED-DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Published date:
06/09/2021
Excerpt:
Eligible pts were aged ≤70 y and had not received previous treatment for CLL/SLL. Pts received 3 cycles of I then 12 cycles of I+V (I 420 mg/d orally; V ramp-up to 400 mg/d orally)….In the 27 pts with del(17p)/TP53 mutation, CR rate was 56%...
DOI:
https://doi.org/10.1002/hon.2879
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.

Published date:
05/21/2021
Excerpt:
In pts with del(17p)/TP53 mutation (n=27), CR rate was 56%, uMRD rate was 81% (PB) and 41% (BM), and 24-mo PFS was 84% (95% CI 63–94). Of 34 pts with high baseline TLS risk based on tumor burden, 32 (94%) shifted to medium or low risk after I lead-in; no TLS occurred....First-line I+V is an all-oral, once-daily, chemotherapy-free, fixed-duration regimen that provides deep, durable responses in pts with CLL/SLL, including those with genomic high-risk features.
DOI:
10.1200/JCO.2021.39.15_suppl.7501
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.

Published date:
05/19/2021
Excerpt:
In pts with del(17p)/TP53 mutation (n=27), CR rate was 56%, uMRD rate was 81% (PB) and 41% (BM), and 24-mo PFS was 84% (95% CI 63–94)….First-line I+V is an all-oral, once-daily, chemotherapy-free, fixed-duration regimen that provides deep, durable responses in pts with CLL/SLL, including those with genomic high-risk features.
DOI:
10.1200/JCO.2021.39.15_suppl.7501
Trial ID: